trial

Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes

NCTId NCT00338949
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 77 (actual)
Sponsored by Veterans Medical Research Foundation
Primary completion 2009-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
77 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2006-06
Primary completion
2009-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Switch

Sponsors

Veterans Medical Research FoundationLead Sponsor
National Institute of Mental Health (NIMH)Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Collaborator

Investigators

1
Jonathan M. Meyer, MDPrincipal Investigator

Sites

1 total
San Diego, United States

Facts & assertions

4 sourced
Enrollment
77
Phase
PHASE4
Primary Completion Date
2009-12
Status
COMPLETED
relationships
The graph out of here
drug
Switch
drug
lead_sponsor
Veterans Medical Research Foundation
company
collaborator
National Institute of Mental Health (NIMH)
company
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Insulin Resistance
indication
Metabolic Syndrome
indication
Psychotic Disorders
indication
investigator
Jonathan M. Meyer, MD
person